netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 30 of 86

Older Oldest

Details
UPD sitematrix Changed from 0 to
09/07/2023 21:36:41
(dmcdermott )
UPD FurtherInformation Changed from
09/07/2023 21:36:41
(dmcdermott )
UPD Nivolumab (Opdivo®) 876
09/07/2023 21:36:41
(dmcdermott )
LDL Link Added : NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer : https://www.nice.org.uk/guidance/ta876
09/07/2023 21:35:42
(dmcdermott )
UPD sitematrix Changed from 0 to
09/07/2023 21:12:23
(dmcdermott )
UPD FurtherInformation Changed from
09/07/2023 21:12:23
(dmcdermott )
UPD Nivolumab (Opdivo®) extra nice ta865
09/07/2023 21:12:23
(dmcdermott )
LDL Link Added : NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma : https://www.nice.org.uk/guidance/ta865
09/07/2023 21:10:26
(dmcdermott )
LDL Link Added : MHRA Drug Safety Update (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation : https://www.gov.uk/drug-safety-update/nivolumab-opdivo-reports-of-cytomegalovirus-cmv-gastrointestinal-infec
06/07/2023 14:18:37
(rpaylor )
LDL Link Added : MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection : https://www.gov.uk/drug-safety-update/nivolumab-opdivo-pembrolizumab-keytruda-reports-of-organ-transplant
06/07/2023 14:18:11
(rpaylor )
LDL Link Added : NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer : https://www.nice.org.uk/guidance/ta724
06/07/2023 14:17:43
(rpaylor )
LDL Link Added : NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy : https://www.nice.org.uk/guidance/ta530
06/07/2023 14:17:17
(rpaylor )
LDL Link Added : NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy : https://www.nice.org.uk/guidance/ta713
17/11/2022 14:18:33
(DavidS )
UPD sitematrix Changed from 0 to
17/11/2022 14:18:08
(DavidS )
UPD FurtherInformation Changed from
17/11/2022 14:18:08
(DavidS )
UPD Nivolumab (Opdivo®) NICE TA713
17/11/2022 14:18:08
(DavidS )
LDL Link Added : NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma : https://www.nice.org.uk/guidance/ta818
15/11/2022 16:42:22
(DavidS )
UPD sitematrix Changed from 0 to
15/11/2022 16:42:01
(DavidS )
UPD FurtherInformation Changed from
15/11/2022 16:42:01
(DavidS )
UPD Nivolumab (Opdivo®) NICE TA818
15/11/2022 16:42:01
(DavidS )
LDL Link Added : NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence : https://www.nice.org.uk/guidance/ta817
15/11/2022 16:33:19
(DavidS )
UPD sitematrix Changed from 0 to
15/11/2022 16:32:57
(DavidS )
UPD FurtherInformation Changed from
15/11/2022 16:32:57
(DavidS )
UPD Nivolumab (Opdivo®) NICE TA817
15/11/2022 16:32:57
(DavidS )
UPD Published from Draft Mode
27/07/2022 16:23:41
(LoweryM )
UPD sitematrix Changed from 0 to
27/07/2022 14:51:26
(DavidS )
UPD BlueTeq Changed from N to Y
27/07/2022 14:51:26
(DavidS )
UPD Nivolumab (Opdivo®) updated
27/07/2022 14:51:26
(DavidS )
UPD sitematrix Changed from 0 to
27/07/2022 14:39:56
(DavidS )
UPD Nivolumab (Opdivo®) brand name added
27/07/2022 14:39:56
(DavidS )

 

 
netFormulary